Early Metabolic Response in Locally Advanced Esophageal Cancer Undergoing Induction Chemoradiotherapy
Early metabolic response evaluation may predict clinical and histopathological response after neoadjuvant chemotherapy. Its value in neoadjuvant chemoradiotherapy (CRT) is unknown. Our aim was to assess the value of early metabolic response after one cycle of chemotherapy using 18-FDG-PET-CT to predict pathological response and outcome in cT2-4 N0/+ esophageal cancer treated by neoadjuvant CRT and esophagectomy.
Esophageal Carcinoma (Squamous Cell Carcinoma - Adenocarcinoma)
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Early Metabolic Response Evaluation With 18-FDG PET-CT in Esophageal Cancer Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy|
- early metabolic response to predict pathological response and outcomeassess the value of early metabolic response with 18-FDG-PET-CT (i.e. a decrease of ≥ 35% of SUVmean) after a single cycle of chemotherapy followed by neoadjuvant CRT and esophagectomy as a tool to predict pathological response and outcome in patients with cT2-4N0/+ carcinoma of the esophagus and GE-junction (GEJ).
- to study correlations between early metabolic response, late metabolic response, histopathological response and outcome.
|Study Start Date:||January 2004|
|Study Completion Date:||December 2009|
|Primary Completion Date:||July 2008 (Final data collection date for primary outcome measure)|
|locally advanced esophageal carcinoma (cT2-3N0/+)||Other: 18-FDG-PET-CT|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01269970
|Leuven, Vlaams-Brabant, Belgium, 3000|